Background/Aims: Long non-coding RNAs (lncRNAs) are key players in the development and progression of human cancers. The lncRNA XIST (X-inactive specific transcript) has been shown to be upregulated in human non-small cell lung cancer (NSCLC); however, its role and molecular mechanisms in NSCLC cell progression remain unclear. Methods: qRT-PCR was conducted to assess the expression of XIST and miR-186. Cell proliferation was detected using MTT assay. Cell invasion and migration were evaluated using transwell assay. Cell cycle distribution and apoptosis rates were analyzed by flow cytometry. Luciferase reporter assay was used to identify the direct regulation of XIST and miR-186. A RNA immunoprecipitation was used to analyze whether XIST was associated with the RNA-induced silencing complex (RISC). Results: We confirmed that XIST was upregulated in NSCLC cell lines and tissues. Functionally, XIST knockdown inhibited cancer cell proliferation and invasion, and induced apoptosis in vitro, and suppressed subcutaneous tumor growth in vivo. Mechanistic investigations revealed a reciprocal repressive interaction between XIST and miR-186-5p. Furthermore, we showed that miR-186-5p has a binding site for XIST. Our data also indicated that XIST and miR-186-5p are likely in the same RNA induced silencing complex. Conclusion: Together, our data revealed that XIST knockdown confers suppressive function in NSCLC and XIST may be a novel therapeutic marker in this disease.
Introduction
Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, which are the primary cause of cancer-related deaths worldwide [1] . Despite advances in the early diagnosis and treatment of lung cancer, the prognosis of lung cancer patients remain poor, with the five-year overall survival rates currently at 18% [2] . Hence, an improved and detailed understanding of the molecular mechanisms underlying NSCLC progression is desperately needed. Recently, increasing evidence has shown that long non-coding RNAs (lncRNAs) provide new insights into the treatment of NSCLC pathogenesis.
Protein-coding genes account for only 2% of the human genome, whereas the vast majority of transcripts are non-coding RNAs (ncRNAs), including microRNA (miRNAs) and lncRNAs [3] . A number of microRNAs were found to act as oncogenes or tumor suppressor genes by previous reports [4] , whereas the mechanism of action for long ncRNAs (lncRNAs) remains largely unknown. LncRNAs are a class of non-coding RNA greater than 200 nucleotides with no protein-coding potential [5] . LncRNAs play critical roles in numerous biological processes, such as epigenetic regulation, nuclear import, cell cycle control, imprinting, differentiation, alternative splicing, RNA decay and transcription [6, 7] . Recent studies have revealed that the expression of lncRNAs is frequently dysregulated in cancers including NSCLC, and is usually correlated with cancer progression, metastasis and poor prognosis [8, 9] . For example, Wan et al. found that the lncRNA plasmacytoma variant translocation 1 (PVT1) promoted NSCLC proliferation by epigenetically regulating large tumor suppressor kinase 2 (LATS2) expression [10] . LncRNA-urothelial carcinoma-associated 1 (UCA1) exerts oncogenic functions in NSCLC by targeting miR-193a-3p [11] . A complete understanding of the roles of lncRNAs in NSCLC would greatly advance the development of novel therapeutic strategies.
The lncRNA XIST (X-inactive specific transcript), a product of the XIST gene, is the master regulator of X inactivation in mammals, and XIST is exclusively transcribed from the inactive X chromosome [12] . XIST is highly expressed in some carcinomas including breast cancer [13] , glioblastoma [14] and ovarian cancer [15] , suggesting that XIST may serve as a biomarker for the diagnosis of these cancers. A recent study showed that XIST is upregulated and is essential for the long term survival of NSCLC [16] ; however, its molecular role in NSCLC has not been clarified.
In this study, we first confirmed that XIST expression was increased in NSCLC cell lines and tissues. Next, we showed that XIST knockdown inhibited NSCLC proliferation and invasion in vitro and suppressed tumor growth in vivo. Finally, miR-186-5p was found to block the oncogenic functions of XIST in NSCLC cells. Therefore, our study identifies XIST as a novel therapeutic target for NSCLC treatment.
Materials and Methods

Tissue specimens
We obtained 30 paired NSCLC and adjacent non-cancerous lung tissues from patients who had undergone surgeries at The First Hospital of China Medical University. All patients had not received chemotherapy or radiotherapy before surgery. All collected tissue samples were immediately snap-frozen in liquid nitrogen and stored at −80ºC until total RNA was extracted. This study was approved by The First Hospital of China Medical University, and it was performed in compliance with the Declaration of Helsinki Principles. Written informed consent was obtained from all patients.
Cell culture and transfection
The NSCLC cell lines (A549, H1299, SK-MES-1 and Calu-3) and the immortalized human bronchial epithelial cell line (BEAS-2B) were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The human NSCLC cell lines were cultured in Dulbecco's Modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) medium or RPMI 1640 medium (Invitrogen). Transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol.
Quantitative real-time PCR
Total RNA from tissues and cells was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. First strand cDNA was generated using the Reverse Transcription System Kit (Takara, Dalian, China). Quantitative real-time PCR (qRT-PCR) analyses utilized SYBR Green I (Takara) and were performed in triplicate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6 snRNA were used as endogenous controls. The relative fold change in expression was calculated by the 2 −ΔΔCt method.
Western blotting
Total proteins were extracted from cells using RIPA buffer and quantified using a bicinchoninic acid (BCA) protein quantification kit (Beyotime Institute of Biotechnology, Jiangsu, China). Protein was separated using 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Membranes were incubated with primary antibodies and GAPDH. Immunoreactive bands were visualized using the Pierce ECL Western Blotting Substrate (Santa Cruz Biotechnology).
Plasmid constructs and cell transfection
Specific siRNA oligonucleotides against XIST (siXIST) and negative control (siNC) were purchased from GenePharma (Shanghai, China). Lentivirus expressing short-hairpin RNA directed against human lncRNA XIST were also purchased from GenePharma. The complementary DNA encoding XIST was PCR-amplified and inserted into pcDNA3.1 (Invitrogen). miR-186-5p mimics and negative control were purchased from Life Technologies (Ambion, Grand Island, NY, USA). The transfection of cells was carried out using Lipofectamine 2000.
Cell viability, cell cycle, cell invasion and apoptosis assay
The 3-(4, 5-dimethylthiazole-2-yl)-2, 5-biphenyl tetrazolium bromide (MTT) assay was performed to test cell viability. Briefly, cells were seeded into 96-well plates at a density of 5 × 10 3 cells/well. The spectrophotometric absorbance was measured for each sample at 570 nm at the indicated time points. Cell migration was evaluated by the wound healing assay, cells were seeded in 24-well plates, and the cell monolayer was scratched with the tip of a sterile 200μL pipette tip. The healing process was observed for 24 h to evaluate the migratory ability of tested cells. The invasive potential was determined using transwell chambers (8μm pore; BD Biosciences). Cells were seeded in the top chamber of the inserts, and the cells that invaded to the lower compartment were fixed with methanol and stained with 0.1% crystal violet. The number of invading cells was calculated by counting five random fields under a microscope. Cell cycle and apoptosis analyses were performed using propidium iodide (Keygen, Nanjing, China) and phycoerythrin (PE) Annexin apoptosis detection kit (BD Pharmingen, San Jose, CA, USA). The cell cycle distribution and apoptosis rates were analyzed by flow cytometry (Epics Altra, Beckman Coulter, USA).
Luciferase reporter assay
To construct dual luciferase reporter plasmids, the theoretical binding sequence of miR-186-5p in XIST and its mutated sequence were separately cloned into pmirGLO Dual-luciferase vectors (GenePharma). HEK-293T cells were co-transfected with wild-type pmirGLO-XIST (XIST-Wt) or the mutated XIST (XISTMut) reporter plasmid and miR-186-5p mimics or negative control using Lipofectamine 2000 (Invitrogen). After 48h, luciferase activity was detected using the dual-luciferase reporter kit (Promega, Madison, WI, USA). The relative firefly luciferase activity was calculated by normalizing to renilla luciferase activity.
RNA immunoprecipitation
A RNA immunoprecipitation was used to analyze whether XIST was associated with the RNA-induced silencing complex (RISC). A549 and H1299 cells were lysed and incubated with RIPA buffer containing magnetic beads conjugated with human anti-Argonaute2 (Ago2) antibody (Millipore). Normal mouse IgG (Millipore) was used as a negative control. Samples were incubated with Proteinase K, and then immunoprecipitated RNA was extracted. Purified RNA was subjected to qRT-PCR analysis.
Xenograft mouse model. LV-NC-or LV-shXIST-infected A549 cells (2×10 6 ), were subcutaneously injected into nude mice. Tumor volumes were measured (0.5 × length × width 2 ) in mice every three days. After 4 weeks, the mice were sacrificed, and the tumors were removed and weighed. All experiments were performed and conformed to the Principles of Laboratory Animal Care (National Society for Medical Research).
Statistical analysis
The data are presented as mean ± standard error from at least three separate experiments. Differences among groups were analyzed by Student's t-test or one-way ANOVA. P values<0.05 were considered statistically significant. All statistical analyses were conducted using SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
XIST expression is upregulated in NSCLC tissues and cell lines
To determine the role of XIST in NSCLC progression, we first measured XIST expression levels in four human NSCLC cell lines (A549, H1299, Calu-3 and SK-MES-1) and a human bronchial epithelial cell line (BEAS-2B). Higher expression of XIST was observed in all NSCLC cell lines tested compared with the human bronchial epithelial cell line (Fig. 1A) . Next, we detected XIST expression in 30 pairs of NSCLC and adjacent normal lung tissues. As shown in Fig. 1B , XIST expression was higher in NSCLC tissues than in paired adjacent normal lung tissues. All data indicated that XIST was frequently up-regulated in NSCLC.
XIST knockdown inhibited NSCLC malignancy
To explore whether XIST has a role in the pathogenesis of NSCLC, XIST was silenced in the high-expressing A549 and H1299 cell lines using siXIST; siNC was the negative control ( Fig. 2A) . We found that the expression of proliferation-and invasion-related proteins, including proliferating cell nuclear antigen (PCNA), recombinant cyclin D1 (CCND1), B-cell lymphoma-2 (Bcl2), and matrix metallopeptidase 9 (MMP9) was decreased after XIST knockdown (Fig. 2B) . As demonstrated by MTT assays, repression of XIST decreased the cell viability in A549 and H1299 cells (Fig. 2C) . Flow cytometry indicated significant induction of S arrest and promotion of G0/G1 fraction in A549 and H1299 cells transfected with siXIST (Fig. 2D) . Similarly, XIST knockdown also induced significantly higher levels of apoptosis (Fig. 2E ) and suppressed cell migration (Fig. 2F) and invasion (Fig. 2G ) in A549 and H1299 cells compared with the negative control group. These results revealed that XIST knockdown inhibited several malignancy parameters of NSCLC cells in vitro.
XIST knockdown suppressed NSCLC tumorigenesis in vivo
We established a mouse xenograft model to examine whether XIST knockdown could impact tumor growth in vivo. A549 cells infected with LV-shXIST or LV-NC were subcutaneously injected into nude mice. After 30 days, the tumor size was decreased in the LV-shXIST group compared with the control group (Fig. 3A) . Knockdown of XIST suppressed control IgG immunoprecipitates (Fig. 4D) . These findings demonstrated that XIST and miR-186-5p are probably in the same RISC complex in NSCLC cells.
miR-186-5p mediates the tumor-suppressive effects of XIST knockdown on NSCLC proliferation and invasion
To analyze the importance of miR-186-5p in XIST-mediated NSCLC proliferation and invasion, we overexpressed miR-186-5p in A549 cells transfected with XIST. The results showed that miR-186-5p overexpression blocked the oncogenic effects of XIST on cell proliferation and invasion (Fig. 5A-5D ), suggesting that the effects of XIST on NSCLC growth and invasion are partially mediated by miR-186-5p.
Discussion
Numerous studies have shown that ncRNAs play key roles in cancer pathogenesis and could offer a new insight into the biology of the disease. ncRNAs are divided into two groups, small non-coding RNAs and lncRNAs. Over the past decade, small non-coding RNAs, such as miRNAs, have been extensively studied, and their roles in gene regulation and cell function have been elucidated in numerous cancers [23] [24] [25] [26] [27] . Recent studies have indicated that lncRNA also participate in several different biologic processes and play oncogenic or tumor suppressive roles during tumorigenesis [28] [29] [30] . However, the roles of lncRNAs in NSCLC remain largely unknown. Understanding the molecular mechanism through which lncRNAs function would accelerate the development of lncRNA-directed diagnostics and therapeutics against cancers [31] .
Previous study has been reported that the lncRNA XIST was upregulated in NSCLC [16] . However, the role and mechanism of XIST in NSCLC remained unknown. In this study, we confirmed that XIST expression was upregulated in NSCLC cell lines and tissues. Furthermore, we determined the effects of XIST knockdown on the biological behaviors of NSCLC cells in vitro, indicating that XIST knockdown suppressed NSCLC cell proliferation and invasion. We also confirmed that XIST knockdown inhibited tumor growth in vivo. All data showed that XIST knockdown exerted suppressive effects in NSCLC.
Recently, ceRNA hypothesis has been proposed and several studies have confirmed the interaction between lncRNA and miRNA in cancer. An example of this type of regulation was exemplified by cancer susceptibility candidate 2 (CASC2), whose decreased expression is in part due to its oncogenic effects on the expression and activity of miR-18a in colorectal cancer [32] . Similar studies have revealed that long noncoding RNA activated by TGF-β (lncRNA-ATB) upregulates ZEB1 and ZEB2 expression by competitively binding the miR-200 family, which induces epithelial-mesenchymal transition (EMT) and invasion in hepatocellular carcinoma [33] . We hypothesized that XIST may act as a ceRNA in NSCLC. Bioinformatics databases were used to search for miRNAs that contained XIST binding sites. miR-186-5p was confirmed as one of the miRNAs which could regulate XIST expression in NSCLC. We found that there was reciprocal repression between XIST and miR-186-5p. Moreover, we have validated the direct binding ability of the predicted miR-186-5p binding site on the XIST by luciferase reporter assays. We also indicated that XIST and miR-186-5p are in the same RISC complex. We further found that miR-186-5p could rescue the effects that knockdown of XIST exerted. These results revealed that XIST knockdown may suppress NSCLC proliferation and invasion through acting as miR-186-5p sponge and indicated a novel XIST-miR-186-5p regulatory axis in NSCLC.
Taken together, our data show that XIST expression is increased in NSCLC cell lines and tissues. XIST knockdown inhibited cell proliferation and invasion as well as inducing apoptosis in NSCLC. Moreover, miR-186-5p mediated the tumor-suppressive effects that knockdown of XIST exerted. Our study suggests a novel regulatory network for NSCLC proliferation, invasion and provides new information for use in the diagnosis and treatment of NSCLC.
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